scholarly journals Craniospinal irradiation in the treatment of chemotherapy refractory leptomeningeal metastasis from breast cancer: A case report

2021 ◽  
Author(s):  
Daniel Tesolin ◽  
Dimitrios Vergidis ◽  
Kevin Ramchandar
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Leptomeningeal Metastasis ◽  
Craniospinal Irradiation

scholarly journals Leptomeningeal Metastasis in a Breast Cancer Treated with Two Lines of Intrathecal Chemotherapy – a Case Report

2019 ◽  
Vol 32 (2) ◽  
Author(s):  
Vanda Mikudova ◽  
Katarina Rejlekova ◽  
Jan Gyarfas ◽  
Iveta Oravcova ◽  
Michal Chovanec ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Leptomeningeal Metastasis ◽  
Intrathecal Chemotherapy

Radiologic Findings of Male Breast Cancer: A Case Report

1994 ◽  
Vol 31 (4) ◽  
pp. 759
Author(s):  
Kyung Joo Park ◽  
Chun Hwan Han ◽  
Jeong Geun Yi ◽  
Joo Hyuk Lee
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Radiologic Findings

scholarly journals LPTO-06. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i7-i7
Author(s):  
Jiaojiao Deng ◽  
Sophia Chernikova ◽  
Wolf-Nicolas Fischer ◽  
Kerry Koller ◽  
Bernd Jandeleit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Tumors ◽  
Cell Lines ◽  
Chemotherapeutic Agent ◽  
Leptomeningeal Metastasis ◽  
Breast Cancer Cell Lines ◽  
Normal Brain ◽  
Breast Cancers

Abstract Leptomeningeal metastasis (LM), a spread of cancer to the cerebrospinal fluid and meninges, is universally and rapidly fatal due to poor detection and no effective treatment. Breast cancers account for a majority of LMs from solid tumors, with triple-negative breast cancers (TNBCs) having the highest propensity to metastasize to LM. The treatment of LM is challenged by poor drug penetration into CNS and high neurotoxicity. Therefore, there is an urgent need for new modalities and targeted therapies able to overcome the limitations of current treatment options. Quadriga has discovered a novel, brain-permeant chemotherapeutic agent that is currently in development as a potential treatment for glioblastoma (GBM). The compound is active in suppressing the growth of GBM tumor cell lines implanted into the brain. Radiolabel distribution studies have shown significant tumor accumulation in intracranial brain tumors while sparing the adjacent normal brain tissue. Recently, we have demonstrated dose-dependent in vitro and in vivo anti-tumor activity with various breast cancer cell lines including the human TNBC cell line MDA-MB-231. To evaluate the in vivo antitumor activity of the compound on LM, we used the mouse model of LM based on the internal carotid injection of luciferase-expressing MDA-MB-231-BR3 cells. Once the bioluminescence signal intensity from the metastatic spread reached (0.2 - 0.5) x 106 photons/sec, mice were dosed i.p. twice a week with either 4 or 8 mg/kg for nine weeks. Tumor growth was monitored by bioluminescence. The compound was well tolerated and caused a significant delay in metastatic growth resulting in significant extension of survival. Tumors regressed completely in ~ 28 % of treated animals. Given that current treatments for LM are palliative with only few studies reporting a survival benefit, Quadriga’s new agent could be effective as a therapeutic for both primary and metastatic brain tumors such as LM. REF: https://onlinelibrary.wiley.com/doi/full/10.1002/pro6.43

Sign in / Sign up

Export Citation Format

Share Document